+

EP0836604A1 - Nouveaux composes azabicycliques substitues - Google Patents

Nouveaux composes azabicycliques substitues

Info

Publication number
EP0836604A1
EP0836604A1 EP96921918A EP96921918A EP0836604A1 EP 0836604 A1 EP0836604 A1 EP 0836604A1 EP 96921918 A EP96921918 A EP 96921918A EP 96921918 A EP96921918 A EP 96921918A EP 0836604 A1 EP0836604 A1 EP 0836604A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
azabicyclo
methylene
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96921918A
Other languages
German (de)
English (en)
Inventor
Preben H. Olesen
John Bondo Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0836604A1 publication Critical patent/EP0836604A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Definitions

  • the present invention relates to heterocyclic compounds which are cholinergic ligands selective for neuronal nicotinic channel receptors, to methods for their preparation, to pharmaceutical compositions comprising them, and to their use in treating cognitive, neurological and mental disorders, which are characterized by decreased nicotinic cholinergic function.
  • the invention also relates to a method of treating Parkinson's disease by modulating the process of dopamine secretion, a method of treating or preventing withdrawal symptom ' s caused by cessation of chronic or long term use of tobacco products, as well as a method for treating obesity.
  • Nicotinic and muscarinic receptors are the two distinct types of choliner ⁇ gic receptors named after their selectivity for muscarine and nicotine, respectively.
  • the cholinergic system is the neurotransmitter system that best correlates with memory and cognitive functions.
  • SDAT a cholinergic hypothesis for senile dementia of the Alzheimer type
  • mAChR muscarinic acetylcholine receptors
  • nAChR nicotinic acetylcholine receptors
  • Parkinson's disease is a debilitating neurodegenerative disease, presently of unknown etiology, characterized by tremors and muscular rigidity.
  • nicotine may also have beneficial effects in PD.
  • Nicotine has also shown beneficial effects in Tourette's syndrome (Sanberg et al., Biomed. Phamacother., Vol. 43, pp. 1 9-23, (1 989)). Alleviation of negative psychotic symptoms, known as the hypofrontality syndrome in schizophrenia, by nicotinic agonists, have been suggested by data showing that nicotine stimulates dopamine release in the nucleus accumbens more potently than in stria ⁇ tum, (Rowell et al.
  • EP 414394 discloses a class of methyleneazabicyclic compounds, substi ⁇ tuted with a five membered heterocyclic ring described as cholinergic compounds which enhance acetylcholine function via an action at mus ⁇ carinic receptors within the central nervous system.
  • the present invention relates to novel substituted azabicyclic compounds of formula I
  • R 5 is H, C ⁇ -alkyl, C 2 . 6 -alkenyl or C 2 . 6 -alkynyl and wherein R 6 is C 2 . 6 -alkyl, C 2 . 6 -alkenyl or C 2 . 6 - alkynyl and wherein R 7 , R 8 , R 9 , R 10 , R 1 , R 2 , R 14 , R 16 , R 18 and R 20 inde ⁇ pendently are hydrogen, C ⁇ -alkyl, C 2 . 6 -alkenyl, C 2 .
  • Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sul ⁇ phate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 .(1977) which are hereby incorporated by reference.
  • the compounds of formula I may exist as geometric and optical isomers and all isomers and mixtures thereof are included herein. Isomers may be separated by means of standard methods such as chromatographic techniques or fractional crystallization of suitable salts.
  • the invention also relates to methods of preparing the above mentioned compounds of formula I. These methods comprise:
  • R 9 , R 10 and R 11 independently are C ⁇ -alkyl, aryl or aralkyl and
  • the pharmacological properties of the compounds of the invention can be illustrated by determining their capability to inhibit the specific binding of 3 H-methylcarbamylcholine ( 3 H-MCC) (Abood and Grassi, Biochem. Phar ⁇ macol., Vol. 35, pp. 41 99-4202, (1 986)).
  • 3 H-MCC 3 H-methylcarbamylcholine
  • 3 H-MCC labels the nicotinic receptors in the CNS.
  • the inhibitory effect on 3 H-MCC binding reflects the affinity for nicotinic acetylcholine receptors.
  • Fresh or frozen rat, brain tissue (hippocampus or cortex) was homoge- nized in assay buffer (50mM Tris-HCI, pH 7.4, 1 20 mM NaCI, 5 mM KCI,
  • Pellets were subsequently reconstituted in assay buffer and an appropri- ate amount of tissue sample was mixed in tubes with 3 H-methylcarba- mylcholine (NEN, NET-951 ; final concentration 2 nM) and test drug. The tubes were incubated at 0 °C for 60 min. Unbound ligand was separated from bound ligand by vacuum filtration through GF/B filters presoaked in 0.5 % polyethylenimine. Filters were washed three times with 5 ml wash buffer (50mM Tris-HCI, pH 7.4) and transferred to vials. 4 ml scintillation fluid was added and the radioactivity was measured by scintillation counting. Unspecific binding was measured with 10 ⁇ M nicotine.
  • 3 H-methylcarba- mylcholine N-methylcarba- mylcholine
  • test drug 3 H-methylcarba- mylcholine
  • the tubes were incubated at 0 °C for 60 min. Unbound ligand was separated from bound ligand by
  • IC 50 values of the test compounds were determined by nonlinear regression analyses (GraphPad InPlot).
  • the pharmacological properties of the compounds of the invention can also be illustrated by determining their capability to inhibit the specific binding of 3 H-Oxotremorine-M ( 3 H-Oxo). Birdsdall N.J.M., Hulme E.C, and Burgen A. S.V. (1 980). "The Character of Muscarinic Receptors in Different Regions of the Rat Brain” . Proc. Roy. Soc. London (Series B) 207, 1 .
  • 3 H-Oxo labels muscarinic receptor in the CNS (with a preference for agonist domains of the receptors).
  • Three different sites are labelled by 3 H- Oxo. These sites have affinity of 1 .8, 20 and 3000 nM, respectively. Using the present experimental conditions only the high and medium affinity sites are determined.
  • the inhibitory effects of compounds on 3 H-Oxo binding reflects the affinity for muscarinic acetylcholine receptors.
  • the homogenizer is rinsed with 1 0 ml of buffer and the combined sus- pension centrifuged for 15 min. at 40,000 x g.
  • the pellet is washed three times with buffer. In each step the pellet is homogenized as before in 2 x 10 ml of buffer and centrifuged for 10 min. at 40,000 x g.
  • the final pellet is homogenized in 20 mM Hepes pH: 7.4 (100 ml per g of original tissue) and used for binding assay. Aliquots of 0.5 ml is added 25 ul of test solution and 25 ul of 3 H-Oxotremorine (1 .0 nM, final concentra ⁇ tion) mixed and incubated for 30 min. at 25°C. Non-specific binding is determined in triplicate using arecoline (1 ug/ml, final concentration) as the test substance. After incubation samples are added 5 ml of ice-cold buffer and poured directly onto Whatman GF/C glass fiber filters under suction and immediately washed 2 times with 5 ml of ice-cold buffer. The amount of radioactivity on the filters are determined by conventional liquid scintillation counting. Specific binding is total binding minus non specific binding.
  • Test substances are dissolved in 10 ml water (if necessary heated on a steam-bath for less than 5 min.) at a concentration of 2.2 mg/ml. 25- 75% inhibition of specific binding must be obtained before calculation of IC 50 .
  • the test value will be given as IC 50 (the concentration (nM) of the test substance which inhibits the specific binding of 3 H-Oxo by 50%).
  • IC 50 (applied test substance concentration) x(C x /C 0 -C x )nM
  • Table I illustrates the affinity of the compounds of the present invention for nicotinic and muscarinic receptors as determined by 3 H-MCC and 3 H-
  • the compounds of the invention are effective over a wide dosage range.
  • dosages from about 0.05 to about 1 00 mg, preferably from about 0.1 to about 1 00 mg, per day may be used.
  • a most preferable dosage is about 1 0 mg to about 70 mg per day.
  • the exact dosage will depend upon the mode of administration, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
  • the route of administration may be any route, which effectively trans ⁇ ports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, subcutaneous, intra ⁇ venous, intraurethral, intramuscular, topical, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
  • oral or parenteral e.g. rectal, transdermal, subcutaneous, intra ⁇ venous, intraurethral, intramuscular, topical, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
  • compositions include a compound of formula I or a pharmaceuti- cally acceptable acid addition salt thereof, associated with a pharmaceuti ⁇ cally acceptable carrier.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
  • the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container for example in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteri ⁇ ously react with the active compounds.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • the compounds are dispensed in unit form comprising from about 1 to about 100 mg in a pharmaceutically acceptable carrier per unit dosage.
  • a typical tablet appropriate for use in this method, may be prepared by conventional tabletting techniques and contains:
  • Triethylamine (2.25 g, 25 mmol) and thionyl chloride (4.0 g, 34 mmol) was added and the reaction mixture slowly heated to room temperature.
  • the reaction mixture was quenched with water ( 1 00 ml) and acidified with concentrated hydrochloric acid.
  • the water phase was extracted with ether (2 x 50 ml), then made alkaline with solid potassium carbonate and extracted with ether (4 x 100 ml).
  • the ether phases were dried over magnesium sulphate and evaporated giving a crude mixture of Z and E isomers.
  • the title compounds were separated by column chro- matography on silica (eluent: ethyl acetate/methanol/ammonium hydrox ⁇ ide: 2/1 /2%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un composé de la formule (I). Dans cette formule, p est égal à 1, m est égal à 0 et n est égal à 1 ou 2, ou p est égal à 1, m est égal à 1 et n est égal à 1, ou p est égal à 2, m est égal à 0 et n est égal à 1. Y correspond à la formule (a). L'invention concerne plus particulièrement des composés hétérocycliques (I) ayant une activité thérapeutique, des procédés pour leur préparation et des compositions pharmaceutiques qui les contiennent. Ces nouveaux composés sont utiles pour traiter des maladies du système nerveux central associées à un dysfonctionnement du système nicotinique-cholinergique.
EP96921918A 1995-06-29 1996-06-28 Nouveaux composes azabicycliques substitues Withdrawn EP0836604A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK75795 1995-06-29
DK75795 1995-06-29
PCT/DK1996/000294 WO1997001558A1 (fr) 1995-06-29 1996-06-28 Nouveaux composes azabicycliques substitues

Publications (1)

Publication Number Publication Date
EP0836604A1 true EP0836604A1 (fr) 1998-04-22

Family

ID=8097204

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96921918A Withdrawn EP0836604A1 (fr) 1995-06-29 1996-06-28 Nouveaux composes azabicycliques substitues

Country Status (4)

Country Link
EP (1) EP0836604A1 (fr)
JP (1) JPH11508541A (fr)
AU (1) AU6299496A (fr)
WO (1) WO1997001558A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009599A1 (fr) * 2002-07-19 2004-01-29 Targacept, Inc. Composes heteroaromatiques olefiniques azacycliques a cinq elements, compositions pharmaceutiques contenant lesdits composes et leur utilisation comme inhibiteurs des recepteurs nicotiniques cholinergiques
AU2004233897A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096285A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (fr) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Conjugues phosphonate / inhibiteur de purine nucleoside phosphorylase
US20080287471A1 (en) 2003-12-22 2008-11-20 Maria Fardis 4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity
DK1778251T3 (da) 2004-07-27 2011-07-18 Gilead Sciences Inc Nukleosidphosphatkonjugater som anti-HIV-midler
PE20110219A1 (es) 2008-07-08 2011-03-31 Gilead Sciences Inc Sales del compuesto n-[(s)({[(2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il]oxi}metil)fenoxifosfinoil]-l-alaninato de etilo como inhibidores de vih
WO2010101967A2 (fr) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Inhibiteurs de phosphothiophène et phosphothiazole vhc polymérase
WO2019027920A1 (fr) 2017-08-01 2019-02-07 Gilead Sciences, Inc. Formes cristallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement d'infections virales

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0363085A3 (fr) * 1988-10-03 1991-03-27 Beecham Group Plc Composés chimiques
GB8917957D0 (en) * 1989-08-05 1989-09-20 Beecham Group Plc Novel compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9701558A1 *

Also Published As

Publication number Publication date
JPH11508541A (ja) 1999-07-27
WO1997001558A1 (fr) 1997-01-16
AU6299496A (en) 1997-01-30

Similar Documents

Publication Publication Date Title
WO1997011072A1 (fr) Nouveaux composes azacycliques ou azabicycliques a substitution
WO1997001558A1 (fr) Nouveaux composes azabicycliques substitues
EP0842172A1 (fr) Nouveaux composes azacycliques et azabicycliques substitues
JP3100160B2 (ja) 複素環式化合物、その調製方法およびその用途
US5591755A (en) Pyridinyl thiadiazolyl compounds for treating glaucoma
JP3517234B2 (ja) 複素環式化合物およびそれらの製法並びに使用
US5677313A (en) Antipsychotic method
US5859004A (en) Use of heterocyclic compounds for the treatment of conditions caused by malfunctioning of the nicotinic cholinergic system
IL94763A (en) R) - (Quinuclidinol esters of converted azacycloalkanoic acids in position 1, their preparation and pharmaceutical preparations containing them
US5936088A (en) Substituted azacyclic or azabicyclic compounds with affinity and selectivity for nicotinic cholinergic receptors
US5994373A (en) Substituted azacyclic compounds
US5182283A (en) Heterocyclic compounds their preparation and use
US5612351A (en) Method of treating urinary bladder dysfunctions
TW390883B (en) Azacyclic or azabicyclic compounds for treating diseases in the central nervous system, their preparation and pharmaceutical composition thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19991202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20000124

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载